Lilly’s Mounjaro Poised to Challenge Novo’s Wegovy in Obesity

[{"selector":"#anim-da30c190-d4ce-4678-9bc3-c995b9acabaa","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-87be400c-ab6f-4056-93f0-d679dd3b12a3","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-21205fdb-f717-46f5-8d65-80c6e340c124","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 1. Eli Lilly's Mounjaro (tirzepatide) met its co-primary and all secondary weight-loss endpoints in the Phase III SURMOUNT-2 study. Gray Frame Corner Gray Frame Corner

2. The study involved adults with Type 2 diabetes (T2D) and obesity or overweight.

[{"selector":"#anim-9954ad00-f8fe-42bd-9bcb-569caabb853d","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-0fb65480-1eb5-474e-b5c9-b2579d7fed6f","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 3. Participants taking the 10-mg dose of Mounjaro experienced a 13.4% average reduction in body weight, while the 15-mg dose led to a 15.7% average weight loss. Gray Frame Corner Gray Frame Corner

4. A higher percentage of participants on Mounjaro achieved a 5% reduction in weight compared to those on a placebo.

[{"selector":"#anim-e03d4693-a7f6-4b78-aa7f-36cacbbf34c2","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-b5bac0c5-836d-403b-8d76-350d92d3afff","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 5. The study was randomized, double-blinded, and placebo-controlled, enrolling 938 participants from various countries. Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-deb9dc78-208b-4f45-98d7-589b3098869a","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 6. Mounjaro's side effects were mostly mild or moderate, with nausea, diarrhea, and vomiting being the most common adverse events. Gray Frame Corner Gray Frame Corner

1. Mounjaro is set to compete with Novo Nordisk's Wegovy in the weight loss market.

[{"selector":"#anim-8aadb8a2-c723-4ac0-bd57-96ea24352439","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-dae0f005-f67a-4f35-871a-b53b40d40be0","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 8. The FDA granted Mounjaro Fast Track designation in October 2022 for the treatment of adults with obesity or overweight and related comorbidities. Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-13869877-ae59-46c8-b92b-e6d061fcf71c","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 9. Lilly has recently posted a Phase IIIb study to compare Mounjaro against Wegovy in obese or overweight participants without T2D. Gray Frame Corner Gray Frame Corner

10. Lilly plans to complete its rolling submission to the FDA for Mounjaro's approval in the coming weeks.

[{"selector":"#anim-c0ec0a40-5a16-450d-8b0e-9213df9db878","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

Swipe up for more BIOMARKER news!

[{"selector":"#anim-42a03318-1554-4130-8157-1cfbc5baa417","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Learn more